Valuation: Ipca Laboratories Limited

Market Cap 451B 4.74B 4.14B 3.81B 3.55B 6.73B 6.83B 45.72B 17.77B 222B 17.79B 17.41B 764B P/E 2026
35.6x
P/E 2027 * 32.3x
Enterprise Value 446B 4.69B 4.1B 3.77B 3.51B 6.66B 6.76B 45.21B 17.57B 219B 17.59B 17.22B 756B EV / Sales 2026
4.24x
EV / Sales 2027 * 4.08x
Free-Float
54.92%
Yield 2026
0.37%
Yield 2027 * 0.33%
1 day+3.46%
1 week+9.92%
Current month+4.58%
1 month+10.22%
3 months+19.53%
6 months+26.70%
Current year+25.37%
1 week 1,616
Extreme 1616
1,788.3
1 month 1,530
Extreme 1530
1,788.3
Current year 1,391.8
Extreme 1391.8
1,788.3
1 year 1,251.6
Extreme 1251.6
1,788.3
3 years 747.5
Extreme 747.5
1,788.3
5 years 669.8
Extreme 669.8
1,788.3
10 years 200
Extreme 200
1,788.3
Manager TitleAgeSince
Chief Executive Officer 53 01/04/2023
Chief Executive Officer 70 01/04/2023
Chief Tech/Sci/R&D Officer 52 16/10/2023
Director TitleAgeSince
Chairman 79 05/07/2012
Director/Board Member 79 28/07/2011
Director/Board Member 53 11/11/2008
Date Insider Type Main position Quantity % Market Cap.
19/12/24Sell 4,000,000 1.5766%
Change 5-day change 1-year change 3-year change Capi.($)
+3.46%+9.92%+25.03%+138.44% 4.74B
+1.86%+0.48%+55.50%+163.08% 1,082B
+3.57%+3.29%+68.60%+61.03% 633B
+3.99%+3.05%+37.93%+93.37% 461B
+3.86%+1.64%+31.35%+24.29% 338B
-0.56%+0.96%+39.86%+36.64% 299B
-0.08%+1.30%+30.37%+44.02% 291B
-1.54%+2.81%-27.56%-39.45% 222B
+3.55%+4.41%+25.45%+66.28% 202B
+4.21%+2.65%+17.47%+71.11% 163B
Average +2.23%+5.11%+30.40%+65.88% 369.71B
Weighted average by Cap. +2.25%+5.54%+41.76%+83.08%

Financials

2026 2027 *
Net sales 96.62B 1.01B 887M 815M 760M 1.44B 1.46B 9.79B 3.8B 47.49B 3.81B 3.73B 164B 108B 1.13B 989M 909M 847M 1.61B 1.63B 10.91B 4.24B 52.95B 4.25B 4.16B 182B
Net income 11.21B 118M 103M 94.57M 88.15M 167M 170M 1.14B 441M 5.51B 442M 432M 18.98B 14.04B 147M 129M 118M 110M 209M 213M 1.42B 553M 6.9B 553M 541M 23.78B
Net Debt -5.02B -52.69M -46.06M -42.33M -39.46M -74.84M -75.98M -508M -198M -2.47B -198M -194M -8.5B -11.82B -124M -109M -99.77M -92.99M -176M -179M -1.2B -466M -5.81B -466M -456M -20.03B
Logo Ipca Laboratories Limited
Ipca Laboratories Limited is an India-based integrated pharmaceutical company. The Company is engaged in manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The Company’s products are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc. and Ipca Pharma Nigeria Ltd.
Employees
16,778
Date Price Change Volume
03/07/26 ₹1,778.90 +3.46% 571,448
02/07/26 ₹1,719.40 +1.36% 172,457
01/07/26 ₹1,696.40 -0.27% 222,143
30/06/26 ₹1,701.00 +3.27% 919,073
29/06/26 ₹1,647.20 +1.79% 333,883
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
1,778.90INR
Average target price
1,719.61INR
Spread / Average Target
-3.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IPCALAB Stock